On 7 January 2010, the European Commission announced a formal investigation into alleged breaches of Articles 101 & 102 TFEU (formerly Articles 81 & 82 EC) by Lundbeck, a pharmaceutical company. Lundbeck is suspected of limiting entry into the market of generic versions of its anti-depressant drug Citalopram. The competition inquiry is at a very early stage, and it may be some time before there are any formal findings with respect to the allegations.